FDA & CDC Recommend Pause of IXCHIQ (Chikungunya Vaccine, Live) for Adults 60+ — An Investigative Update

Published: May 12, 2025 (FDA safety communication).
Quick summary: The FDA and CDC have recommended a temporary pause in the use of IXCHIQ® (Chikungunya Vaccine, Live) for people 60 years and older while agencies investigate postmarketing reports of serious neurologic and cardiac events, including deaths. This article explains what’s known, what the agencies are doing, who’s at risk, and exactly what vaccine manufacturers should do now. U.S. Food and Drug Administration

What happened — the facts (short)

The FDA posted a safety communication on May 12, 2025, recommending a pause in IXCHIQ use for individuals 60+ while an updated benefit–risk assessment is conducted. U.S. Food and Drug Administration
As of May 7, 2025, there were 17 serious adverse event (SAE) reports globally among recipients aged 62–89, including two deaths; six of these reports were from the United States. U.S. Food and Drug Administration
Roughly 80,000 doses of IXCHIQ had been distributed worldwide at the time of the notice. U.S. Food and Drug Administration
Some reported events resemble severe complications of chikungunya disease (e.g., encephalitis); the FDA notes that postmarketing reports may not be causally related to the vaccine. U.S. Food and Drug Administration

Why this matters — clinical and public-health context

IXCHIQ is a live, attenuated chikungunya vaccine approved in November 2023 for adults ≥18 years at increased risk of exposure. Because it contains a live, weakened virus, it can—rarely—produce chikungunya-like illness as a vaccine reaction. In the vaccine clinical program, 1.6% of vaccine recipients experienced severe chikungunya-like adverse reactions (two hospitalizations reported), and some participants had prolonged symptoms ≥30 days—findings the FDA highlighted in its communication. These trial signals, combined with the emerging postmarketing reports in older adults, prompted the pause recommendation. U.S. Food and Drug Administration

What the FDA and CDC are doing (agency actions)

Recommendation of a temporary pause (use in people ≥60) while agencies complete an updated benefit–risk assessment focused on older adults. U.S. Food and Drug Administration
Ongoing review of postmarketing safety reports submitted to VAERS and other surveillance systems; FDA and CDC will update the public when the evaluation is complete. U.S. Food and Drug Administration
Advisory and reporting requests: healthcare professionals and patients are urged to report adverse events to VAERS to support surveillance. U.S. Food and Drug Administration

Known numbers and patterns (what’s load-bearing)

17 serious AEs globally (ages 62–89); 6 from the U.S. (data current to May 7, 2025). U.S. Food and Drug Administration
2 deaths reported in the affected age group. U.S. Food and Drug Administration
~80,000 doses distributed globally — relatively limited exposure, magnifying the signal’s importance. U.S. Food and Drug Administration
Clinical-trial signal: 1.6% experienced severe chikungunya-like adverse reactions; two hospitalizations; some prolonged symptoms. U.S. Food and Drug Administration

Patient- and clinician-facing guidance (what to do now)

For clinicians and vaccinators

Immediately stop offering IXCHIQ to patients aged 60 or older until FDA/CDC lift the pause. Document counseling and vaccine decisions. U.S. Food and Drug Administration
Screen recently vaccinated older patients (especially those with chronic conditions) for new neurologic or cardiac symptoms (confusion, severe headache, focal deficits, chest pain, syncope, palpitations) and escalate care if needed. U.S. Food and Drug Administration
Report any suspected serious events following IXCHIQ to VAERS (vaers.hhs.gov). Timely, detailed reports help regulators assess causality. U.S. Food and Drug Administration

For patients and caregivers

If you are 60 or older and were scheduled or recently vaccinated with IXCHIQ, contact the clinic or your healthcare provider for guidance. Providers will follow agency advisories. U.S. Food and Drug Administration
If you experience new neurologic or cardiac symptoms after vaccination—such as seizures, severe persistent headache, confusion, difficulty breathing, chest pain, fainting—seek urgent medical care and report the event. U.S. Food and Drug Administration

Investigative view: what we don’t yet know (open questions)

Causality: Are the reported SAEs caused by the vaccine, or coincidental events in a population with multiple comorbidities? The FDA explicitly cautions that VAERS reports do not establish causation. U.S. Food and Drug Administration
Risk modifiers: Is age per se the main risk factor, or do comorbidities, immune status, or concurrent medications drive the observed events? Most reports included individuals with chronic illnesses, suggesting comorbidity interplay. U.S. Food and Drug Administration
Dose-responsiveness and lot issues: Is exposure limited to particular lots, cold-chain failures, or administration errors? Public data do not yet show a clustering by lot or site. This is a critical focus for the FDA’s assessment. U.S. Food and Drug Administration

What manufacturers must do — an actionable checklist

The pause and the FDA review create immediate regulatory, operational, and communications priorities for the vaccine sponsor(s). Below is a prioritized, practical checklist vaccine manufacturers should implement immediately.

1. Immediate safety and regulatory actions

Cooperate fully with FDA/CDC requests: provide line-level case data, batch/lot traceability, and unredacted clinical and pharmacovigilance case reports for the 17 SAEs and any other events. U.S. Food and Drug Administration
Prepare an updated benefit–risk dossier focusing on ≥60 age stratum: include clinical-trial subgroup analyses, immunogenicity/ reactogenicity by age, comorbidity stratification, and any animal-model data. U.S. Food and Drug Administration
Support or enable rapid FDA site inspections (manufacturing, lot release, cold-chain records) if requested.

2. Pharmacovigilance & signal management

Expedite case follow-up: obtain hospital records, autopsy reports (if any), lab tests, and timelines for each SAE. Classify events by standard case definitions (e.g., Brighton Collaboration if applicable). U.S. Food and Drug Administration
Perform rapid epidemiologic analyses: observed vs expected rates for neurologic and cardiac events in vaccinated vs background populations (age-adjusted). U.S. Food and Drug Administration
Conduct lot-level and distribution mapping to identify potential clustering by batch, site, or geographic area. U.S. Food and Drug Administration

3. Labeling, communications & HCP support

Prepare multiple communication templates (Dear HCP, Dear Distributor, press statements, website FAQs) ready to deploy once FDA completes its review—transparency is critical. U.S. Food and Drug Administration
Update product information drafts that could be needed if FDA requires label changes (warnings about severe chikungunya-like illness, age-specific precautions, contraindications for certain high-risk groups). U.S. Food and Drug Administration

4. Operational & supply chain actions

Inventory & recall readiness: although no recall has been requested, be prepared to execute targeted recalls by lot if the investigation identifies a production or quality root cause. U.S. Food and Drug Administration
Cold chain and handling audit: verify storage and handling records for distributed lots; correct deviations and retrain staff as needed.

5. Clinical and research follow-up

Sponsor prospective monitoring of recently vaccinated cohorts (especially older adults) to collect active follow-up data (e.g., symptom diaries, phone checks, troponin/ECG if indicated). U.S. Food and Drug Administration
Plan an independent review of serious cases with external experts (infectious disease, neurology, cardiology) to build credibility and objectivity.

6. Legal & risk-management

Engage legal counsel experienced in vaccine safety and regulatory matters to coordinate communications and manage liability exposure.
Document all interactions with regulators and healthcare partners meticulously.

How regulators will assess next (what to expect)

FDA’s updated benefit–risk assessment will weigh the small absolute number of SAEs against vaccine-preventable disease risk for older adults and might recommend:
- Continuing the pause for ≥60,
- Restricting use to narrower high-risk subgroups, or
- Lifting the pause if no causal link is found. U.S. Food and Drug Administration
CDC guidance (ACIP or other CDC panels) may follow to align public-health policy on traveler recommendations and immunization practice. U.S. Food and Drug Administration

Bottom line — takeaways for stakeholders

Clinics & providers: stop using IXCHIQ in patients 60+ until FDA/CDC say otherwise; monitor and report events. U.S. Food and Drug Administration
Patients ≥60: if scheduled for IXCHIQ, contact your provider; if vaccinated and symptomatic, seek care and ensure event is reported. U.S. Food and Drug Administration
Manufacturers: treat the situation as high priority—provide data, map distributions, expedite investigations, and be ready to update labeling and communications rapidly. U.S. Food and Drug Administration

Sources

FDA Safety Communication: “FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated.” Posted 05/12/2025. U.S. Food and Drug Administration

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.